Site Last Updated:

Sign up for your FREE TFN E-NEWS Alert TODAY!

Let Taipan Financial News be your resource for late-breaking investment opportunities.


We value your privacy!

 

Indices: US - World |
Most Actives


Try Taipan Financial News Stock Screener



Taipan Financial News Video Guide

Our Products

Free Newsletters

News Feed

Subscribe to Taipan Financial News Feeds by Email

 Subscribe in a reader

Add to Google

Add to My AOL

Subscribe in Bloglines

PODCAST:

Get Taipan Financial News Podcast On Your I-Tunes

Add Taipan Financial News Feeds to ODEO

Subscribe in podnova

Add to Pageflakes

Premium Membership

Also on TFN

Visit Our New Bookstore
Best Offer

Sponsored by:


tfn declaration seal

 

 

 

Share this story Share this story | Print this story Print this story

Earnings Reports: Season Highlights

By Bryan Bottarelli

Thursday Apr 12, 2007


A Taipan Financial News Market Report (Sign up Free!)

In this article
Research in Motion (RIMM:NASDAQ) is off more than $11 (an 8% haircut) after reporting that its fiscal fourth-quarter profit surged tenfold from a year earlier.
Another tough luck-earnings loser today is Genentech (DNA:NYSE).
This “half empty” trend does not set a rosy picture for Infosys Technologies (INFY:NASDAQ).


Earnings Reports: Season Highlights

Welcome to earnings season, where good news is bad and bad news is good.

In today's trading, for example, Research in Motion (RIMM:NASDAQ) is off more than $11 (an 8% haircut) after reporting that its fiscal fourth-quarter profit surged tenfold from a year earlier.

Its sales rose 66% on strong demand for Blackberry wireless devices -- and yet the stock is getting hammered on the news.

*Sidenote: I've always thought that RIMM was overvalued. In fact, I specifically remember having a conversation with some WaveStrength readers at the Orlando Money Show about RIMM's lofty values and its ability to move down quickly on any less than stellar news. Unfortunately, anytime I tried to play downside puts on RIMM, the stock has rallied. So I guess I needed some incredible earnings news to spark the sell-off, as opposed to the other way around.

Another tough luck-earnings loser today is Genentech (DNA:NYSE). The stock is down $1.59 (nearly 2%) after reporting that its first-quarter profit surged 68% and its sales rose 43% from the same period a year ago. These numbers appeared to be impressive since sales of two of its key cancer treatments came in lower on a sequential basis -- but apparently Wall Street does not consider the glass to be half full.

This “half empty” trend does not set a rosy picture for Infosys Technologies (INFY:NASDAQ). The Bangalore, India firm is expected to announce earnings of $0.40 per share tomorrow -- which happens to be Friday the 13th. I consider INFY a fantastic company -- and I hope that it reports a strong number. But if the stock keeps up the early earnings trend -- which is falling on strong news -- you could have a good buying opportunity.

Next Monday, heavyweights like Citigroup (C:NYSE) and Eli Lilly (LLY:NYSE) report, and Tuesday April 17 will feature Yahoo! (YHOO:NASDAQ). So I'd expect to see some heavy trading in the following weeks -- get set for some earnings-related volatility!

***

Bryan Bottarelli is the head trading tactician for the WaveStrength Group, and is a contributing editor for Taipan Financial News. Coming off the floor of the Chicago Board Options Exchange (CBOE), Bryan uses WaveStrength chart forecasting to develop wining options plays for his service called WaveStrength Options Weekly. Bryan is also the lead editor of BottarelliResearch, an elite membership service that he independently publishes himself.


Did you like this article? Get Market Report everyday! Sign up Free!


Related Articles
Stock Market Exchanges: A Powerful New Investing Trend
Gasoline Consumption: Consumer Lip Service
Blue Chip Investing: Transparent Incompetence

Related Resources
Quote: INFY Highlights. - Yahoo!Finance
Markets: Today's Movers and Shakers. - MarketWatch.com